Literature DB >> 24267303

World Health Organization group 5 pulmonary hypertension.

Tim Lahm1, Murali M Chakinala.   

Abstract

World Health Organization (WHO) group 5 pulmonary hypertension (PH) entails a heterogeneous group of disorders that may cause PH by unclear and/or multiple mechanisms. In particular, group 5 includes PH caused by hematologic disorders, systemic diseases, metabolic disorders, chronic renal failure, and disorders leading to pulmonary vascular occlusion or compression. This article discusses common pathogenic mechanisms leading to group 5 PH, followed by a detailed overview of epidemiology, pathogenesis, and disease-specific management of the individual group 5 conditions. Off-label use of vasomodulatory therapies, typically indicated for pulmonary arterial hypertension (WHO group 1 PH), in group 5 conditions is also discussed.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fibrosing mediastinitis; Lymphangioleiomyomatosis; Metabolic disorders; Myeloproliferative disorders; Pulmonary Langerhans cell histiocytosis; Renal failure; Sarcoidosis; Splenectomy

Mesh:

Substances:

Year:  2013        PMID: 24267303     DOI: 10.1016/j.ccm.2013.08.005

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  6 in total

Review 1.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

2.  Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm.

Authors:  Yalin Tolga Yaylali; Samet Yilmaz; Gulsum Akgun-Cagliyan; Oguz Kilic; Emrah Kaya; Hande Senol; Furkan Ozen
Journal:  Med Princ Pract       Date:  2020-02-19       Impact factor: 1.927

3.  Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series.

Authors:  Inderjit Singh; Geoffrey Mikita; Daniel Green; Cristobal Risquez; Abraham Sanders
Journal:  Pulm Circ       Date:  2017-03-10       Impact factor: 3.017

4.  Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease.

Authors:  Gillian C Goobie; Sandra M Sirrs; John Yee; John C English; Celine Bergeron; Roland Nador; John R Swiston; Pramod K Mistry; Wendy Paquin; Robert D Levy
Journal:  Respir Med Case Rep       Date:  2019-06-29

5.  Using health administrative data to identify patients with pulmonary hypertension: A single center, proof of concept validation study in Ontario, Canada.

Authors:  Don Thiwanka Wijeratne; Ahmad Housin; Katherine Lajkosz; M Diane Lougheed; Ping Yu Xiong; David Barber; Katharine M Doliszny; Stephen L Archer
Journal:  Pulm Circ       Date:  2022-02-04       Impact factor: 2.886

6.  Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute.

Authors:  Anna R Hemnes; David G Kiely; Barbara A Cockrill; Zeenat Safdar; Victoria J Wilson; Manal Al Hazmi; Ioana R Preston; Mandy R MacLean; Tim Lahm
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.